Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62016CA0462

    Case C-462/16: Judgment of the Court (Fifth Chamber) of 20 December 2017 (request for a preliminary ruling from the Bundesfinanzhof — Germany) — Finanzamt Bingen-Alzey v Boehringer Ingelheim Pharma GmbH & Co. KG (Reference for a preliminary ruling — Taxation — Value added tax (VAT) — Directive 2006/112/EC — Article 90(1) — Reduction of the price under conditions determined by the Member States — Reduction of the taxable amount — Principles laid down in the judgment of 24 October 1996, Elida Gibbs (C-317/94, EU:C:1996:400) — Discounts granted to private medical insurance funds)

    IO C 72, 26.2.2018, p. 21–21 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    26.2.2018   

    EN

    Official Journal of the European Union

    C 72/21


    Judgment of the Court (Fifth Chamber) of 20 December 2017 (request for a preliminary ruling from the Bundesfinanzhof — Germany) — Finanzamt Bingen-Alzey v Boehringer Ingelheim Pharma GmbH & Co. KG

    (Case C-462/16) (1)

    ((Reference for a preliminary ruling - Taxation - Value added tax (VAT) - Directive 2006/112/EC - Article 90(1) - Reduction of the price under conditions determined by the Member States - Reduction of the taxable amount - Principles laid down in the judgment of 24 October 1996, Elida Gibbs (C-317/94, EU:C:1996:400) - Discounts granted to private medical insurance funds))

    (2018/C 072/27)

    Language of the case: German

    Referring court

    Bundesfinanzhof

    Parties to the main proceedings

    Applicant: Finanzamt Bingen-Alzey

    Defendant: Boehringer Ingelheim Pharma GmbH & Co. KG

    Operative part of the judgment

    In the light of the principles defined by the Court in the judgment of 24 October 1996, Elida Gibbs (C-317/94, EU:C:1996:400, paragraphs 28 and 31), regarding the determination of the taxable amount for value added tax and having regard to the principle of equal treatment under EU law, Article 90(1) of Council Directive 2006/112/EC of 28 November 2006 on the common system of value added tax must be interpreted as meaning that the discount granted, under national law, by a pharmaceutical company to a private health insurance company results, for the purposes of that article, in a reduction of the taxable amount in favour of that pharmaceutical company, where it supplies medicinal products via wholesalers to pharmacies which make supplies to persons covered by private health insurance that reimburses the purchase price of the medicinal products to persons it insures.


    (1)  OJ C 402, 31.10.2016.


    Top